Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Francesco Locatelli"'
Publikováno v:
Expert Opinion on Pharmacotherapy. 24:287-290
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:781-788
Erythropoiesis-stimulating agents (ESAs) are not perfect, since they have potential side effects. Iron therapy is also receiving growing attention in recent years. Areas covered: We performed a literature search on PubMed using the following key word
Autor:
Lucia Del Vecchio, Francesco Locatelli
Publikováno v:
Expert Opinion on Pharmacotherapy. 13:495-503
Anemia, a frequent and early complication of chronic kidney disease (CKD), not only impairs quality of life but is also an independent risk factor for adverse cardiovascular outcomes. Erythropoiesis-stimulating agents (ESAs), together with iron, are
Publikováno v:
Expert opinion on pharmacotherapy. 15(10)
Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a
Autor:
Lucia Del Vecchio, Francesco Locatelli
Publikováno v:
Expert opinion on pharmacotherapy. 14(10)
Any scientific innovation needs to translate into a significant benefit. Peginesatide is noninferior to other erythropoiesis stimulating agents (ESAs) in terms of efficacy, and it shares the advantages of other long-acting ESAs: delayed administratio